TITLE

FDA APPROVES BIOVAIL'S TEVETEN HCT FOR HYPERTENSION

PUB. DATE
April 2003
SOURCE
Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the U.S. Food and Drug Administration approval of Teveten (R) HCT from Biovail Corp. for the treatment of hypertension, as of April 2003.
ACCESSION #
9427669

 

Related Articles

  • 3-in-1 Combination Gets FDA Approval for Hypertension.  // Journal of Gerontological Nursing;Oct2010, Vol. 36 Issue 10, p29 

    This article reports that the drug Tribenzor for treating hypertension was approved by the U.S. Food and Drug Administration (FDA).

  • Valturna for hypertension.  // Monthly Prescribing Reference;Nov2009, Vol. 25 Issue 11, pA20 

    The article offers information on the approval of the drug Valturna, which contains a direct renin inhibitor and an angiotension receptor blocker (ARB), for the treatment of hypertension.

  • Product UPDATE.  // Pharmaceutical Executive;Jul2003, Vol. 23 Issue 7, p26 

    Reports development related to pharmaceutical industry in the U.S. as of July 2003. Drug approval of Lescol from Novartis to reduce the risk of coronary revascularization in heart disease patients; Effectiveness of olmesartan for the treatment of hypertension; Availability of multiple...

  • Two New Hypertension Tablets Receive Approval.  // Journal of Gerontological Nursing;Apr2011, Vol. 37 Issue 4, p7 

    The article reports on approval which the U.S. Food and Drug Administration gave in 2011 for the use of the antihpertensive agents Amturnide and Edarbi. A discussion of research which was conducted on the efficacy and safety of the two drugs, and which the administration evaluated prior to...

  • Macitentan approved by FDA to delay progression of PAH. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;12/1/2013, Vol. 70 Issue 23, p2054 

    The article reports on the approval of the marketing of the drug macitentan as a treatment to delay progression of the debilitating disease pulmonary arterial hypertension (PAH) by the U.S. Food and Drug Administration (FDA) on October 18, 2013. INSET: New drugs and dosage forms.

  • New Clinical Trials Underway for Pulmonary Arterial Hypertension. Fratantoro, Mike // RT: The Journal for Respiratory Care Practitioners;Nov2014, Vol. 27 Issue 11, p4 

    The article discusses several studies on pulmonary arterial hypertension (PAH), development of pharmacological treatments and the economic aspect of the disease.

  • Germany says two doctors needed to approve some drugs. Tuffs, Annette // BMJ: British Medical Journal (International Edition);11/1/2008, Vol. 337 Issue 7677, p1018 

    The article reports that the German federal joint committee has called for a second doctor's review on prescriptions for patients with pulmonary arterial hypertension. The rule applies to patients who receive hospital treatment from a specialist and those who receive treatment in general...

  • Volibris wins European Commission okay for PAH.  // Cardiovascular Devices & Drugs;May2008, Vol. 14 Issue 5, p20 

    The article reports on the announcement by GlaxoSmithKline that it has received authorization from the European Commission for Volibris, a product for the treatment of pulmonary arterial hypertension (PAH) in patients classified as World Health Organization (WHO) Class II and III, to improve...

  • NEWS.  // Clarendon Enterprise (TX);12/5/2013, Vol. 24 Issue 49, p5 

    The article offers brief information on the drug macitentan with the brand name Opsumit which has been approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH) in adults.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics